Search

Displaying results 4511 - 4520 of 4635 in total
  1. Drug

    Cilansetron

    go.drugbank.com/drugs/DB04885
    Experimental

    Cilansetron is a 5HT-3 antagonist made by Solvay Pharmaceuticals that is currently under trial phase in the EU and US.

  2. Drug

    Renzapride

    go.drugbank.com/drugs/DB04917
    Investigational

    Renzapride is currently in Phase III clinical development in the United States for the treatment of constipation-predominant irritable bowel syndrome (IBS-C). It has been suggested that renzapride is effective in the treatment of irritab...

    Categories: Serotonin 5-HT4 Receptor Agonists
  3. Drug

    Phosphoaminophosphonic Acid-Adenylate Ester

    go.drugbank.com/drugs/DB04395
    Experimental

    5'-Adenylic acid, monoanhydride with imidodiphosphoric acid. An analog of ATP, in which the oxygen atom bridging the beta to the gamma phosphate is replaced by a nitrogen atom.

  4. Drug

    Gataparsen

    go.drugbank.com/drugs/DB05141
    Investigational

    LY2181308 is known to target baculoviral IAP repeat-containing protein 5.

  5. Drug

    Temanogrel

    go.drugbank.com/drugs/DB05227
    Investigational

    APD791 is an oral anti-thrombotic drug candidate being evaluated in a Phase 1 clinical trial by Arena. APD791 is intended to lower the risk of arterial thrombosis by reducing the amplification of platelet aggregation, arterial constricti...

    Categories: Serotonin 5-HT2 Receptor Antagonists
  6. Drug

    Folitixorin calcium

    go.drugbank.com/drugs/DB05308
    Investigational

    ANX-510 (CoFactor) is a folate-based biomodulator drug being developed to enhance the activity and reduce associated toxicity of the widely used cancer chemotherapy, 5-fluorouracil (5-FU). … CoFactor use with 5-FU is being evaluated in clinical trials in first line treatment of metastatic colorectal cancer.

  7. Drug

    OSI-461

    go.drugbank.com/drugs/DB05415
    Investigational

    OSI-461 is a second-generation molecule belonging to a new class of drugs termed selective apoptotic anti-neoplastic drugs (SAANDs).

  8. Drug

    SN-38

    go.drugbank.com/drugs/DB05482
    Investigational

    7-ethyl-10-hydroxycamptothecin (SN 38) is a liposomal formulation of the active metabolite of Irinotecan [DB00762], a chemotherapeutic pro-drug approved for the treatment of advanced colorectal cancer

  9. Drug

    Elacytarabine

    go.drugbank.com/drugs/DB05494
    Investigational

    Elacytarabine is a fatty acid derivative of cytarabine, an approved cytotoxic cancer drug. Cytarabine has limitations such as minimal uptake in solid tumours and is only used to treat leukaemia. Elacytarabine is designed to overcome this...

  10. Drug

    BL-1020

    go.drugbank.com/drugs/DB05687
    Investigational

    BL-1020 is a first in class novel compound for the treatment of schizophrenia. It is being developed by BioLineRx (BioLine).